A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
Sponsor
Alcon Research (Industry)
Overall Status
Completed
CT.gov ID
NCT00051181
Collaborator
(none)
2
41
Study Details
Study Description
Brief Summary
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.
Study Start Date
:
Jan 1, 2000
Actual Primary Completion Date
:
Jun 1, 2003
Actual Study Completion Date
:
Jun 1, 2003
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Asia | Fort Worth | Texas | United States | |
| 2 | Australia | Sidney | Australia |
Sponsors and Collaborators
- Alcon Research
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00051181
Other Study ID Numbers:
- C-01-38
First Posted:
Jan 7, 2003
Last Update Posted:
Aug 5, 2008
Last Verified:
Aug 1, 2008
Keywords provided by ,
,
Additional relevant MeSH terms: